Pharmacokinetics of Ceftolozane/Tazobactam in Patients With Burns

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-08-21

Study Completion Date

2020-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will help provide information about how patients with burn handle two antibiotics (ceftolozane and tazobactam) and use that information to guide dosing recommendations for these patients. The 12 patients who complete the study will receive a single dose of 3 grams ceftolozane/tazobactam intravenously. We will collect blood and urine samples to determine how much of each antibiotic is in the body and urine at various times over a 24 hour period. This information will be used with previously published information from microbiology laboratories to perform simulations that will provide recommendations on optimal dosing recommendations of these antibiotics in patients with burns.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Study on Bacterial Load Following Open-to-air Management in Burn Patients.

NCT04502914

Burns Infection Wound Bacterial Infections

WITHDRAWN NA

Identification and Validation of Biomarkers for Infections in Burns

NCT02457663

Burns Involving 20% or More of Body Surface

TERMINATED

Chronology of Occult and Gross Coagulopathy in Burn Patients

NCT01638481

Thermal Burns

COMPLETED

Comparison of Collagenase With Antibiotic Ointment of Minor Partial Thickness Burns

NCT02673229

Burn, Partial Thickness

TERMINATED PHASE4

Large Burn Outcome Study

NCT00731887

Burns

WITHDRAWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A single dose pharmacokinetic study of ceftolozane and tazobactam will be conducted in patients with burns at the Burn Center at University Medical Center. A total of 12 adults aged 18 to 80 years with \>/= 20% percent total body surface area burned will be required to complete the study. A single intravenous dose of ceftolozane and tazobactam of 2 grams/1 gram will be administered over 60 minutes and whole blood will be obtained predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, and 24 hours following the start of infusion. Urine samples (5 ml) will be collected from a urine collection bag (if the patient has urinated) at the following timepoints: 0-0.5, 0.5-1, 1-2, 2-4, 4-8, 8-12, and 12-24 hours for analysis of ceftolozane and tazobactam content. Urine for collected during each time period will be measured to determine urine volume for urine clearance calculations. The volume of urine in the urine over the entire 24 hour period and an aliquot sent for analysis of urine creatinine content to determine the patient's 24 hour creatinine clearance.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Burns Pharmacokinetics

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ceftolozane/tazobactam

One dose of 3 grams ceftolozane/tazobactam will be administered to each study participant.

Group Type EXPERIMENTAL

Ceftolozane/tazobactam

Intervention Type DRUG

Single dose of 2 grams/1 gram intravenously administered over 60 minutes.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ceftolozane/tazobactam

Single dose of 2 grams/1 gram intravenously administered over 60 minutes.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Zerbaxa

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male and female subjects, ages 18-80 years, of all racial and ethnic origins.
2. Non-English Spanish speakers will be included in the study.
3. We are recruiting 12 patients with thermal burn injuries (percent total body surface area burned \>/= 20%). Patients will be at least five days from the date of the burn injury.
4. Patients will have central venous or arterial line access.
5. Patients will be already be receiving standard of care antimicrobial therapy for a suspected infection.

Exclusion Criteria

1. Pregnant or nursing or unwilling to use a reliable contraception method during the study. The effects of ceftolozane and tazobactam on pregnancy are unknown. In addition, the metabolic changes that accompany pregnancy may alter the concentration-time profile of ceftolozane and tazobactam, so that the pregnancy and post-partum state would be a confounding variable.
2. Abnormal liver function tests: transaminases \>10 times upper limit of normal, Alkaline phosphatase \>5 times upper limit of normal, total bilirubin \>5 times upper limit of normal.
3. History of allergies to beta-lactam antibiotics.
4. Patients unwilling to comply with study procedures.
5. Current or previous participation within 28 days of enrollment in another research study that involves the use of medication, contrast, or any other compound that may alter blood count and/or blood chemistry (liver function, kidney function or electrolyte balance), unless waved by principal investigator (PI).
6. Donation of 450mL (one unit) of blood or more within 8 weeks (56 days) prior to study enrollment, unless waved by PI.
7. Creatinine clearance \< 30 ml/min as estimated by the Cockcroft-Gault equation.
8. Patients who are receiving piperazillin/tazobactam or have received piperacillin/tazobactam within the past 48 hours.
9. Patients who are receiving vasopressors.
10. Patients with a total body weight \< 60 kg or \> 130 kg.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No